NCT02640508View on ClinicalTrials.gov

Eribulin and Lenvatinib in Advanced Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

November 24, 2020

Study Completion Date

January 12, 2023

Conditions
CancerSolid Tumor
Interventions
DRUG

Eribulin

Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.

DRUG

Lenvatinib

Will be taken orally at 20-24 mg daily in each 21 day cycle.

Trial Locations (1)

78229

Cancer Therapy and Research Center University of Texas Health Science Center San Antonio, San Antonio

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Virginia G. Kaklamani

OTHER

NCT02640508 - Eribulin and Lenvatinib in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter